Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine

Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

AbstractPurpose of ReviewAs research efforts have advanced to understand the pathophysiology of viral hemorrhagic fevers (VHF) and other epidemic viral infections and develop medical countermeasures such as vaccines, pregnant women have remained an underexamined subgroup. To better understand the implications of future outbreaks of VHF for pregnant women amidst an evolving vaccine landscape, we examine three pathogens —yellow fever, Ebola, and Lassa fever—each with different levels of evidence and understanding of disease in pregnancy and at varying stages of vaccine development.Recent FindingsThere are very li...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
The Commission on Human Medicines has issued a series of recommendations to strengthen measures to minimise risk with the yellow fever vaccine (Stamaril) following very rare fatal reactions..
Source: Royal Pharmaceutical Society News - Category: Drugs & Pharmacology Source Type: news
Publication date: Available online 20 November 2019Source: Journal of Theoretical BiologyAuthor(s): Zhimin Chen, Kaihui Liu, Xiuxiang Liu, Yijun LouAbstractThe control strategies of emergency infectious diseases are constrained by limited medical resources. The fractional dose vaccination strategy as one of feasible strategies was proposed in response to global shortages of vaccine stockpiles. Although a variety of epidemic models have been developed under the circumstances of limited resources in treatment, few models particularly investigated vaccination strategies in resource-limited settings. In this paper, we develop ...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
[Radio Dabanga] Khartoum -Sudan's federal Ministry of Health and the World Health Organisation (WHO) are working with partners and at-risk communities to scale up surveillance of cholera in Khartoum. On November 7, the final phase of the five-year yellow fever vaccination campaign targeting more than 30 million people across Sudan was launched. According to the Sudan Metrological Authority, rainfall in the country has been persistently above average throughout most of the 2019 season.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
AbstractPurpose of ReviewThis decade has seen a resurgence of yellow fever (YF) that has also affected travelers with a record number of international travelers infected by YF virus including the first documented importation of YF into Asia.Recent FindingsThe recent resurgence of YF has been attributed largely to sub-optimal vaccination coverage along with waning population-level immunity. New lessons have been learnt with regard to the clinical management of severe YF as a result of the Brazilian outbreak. With increasing YF cases in travelers, travel medicine providers need to familiarize themselves with the diagnosis an...
Source: Current Infectious Disease Reports - Category: Infectious Diseases Source Type: research
Condition:   Yellow Fever (Healthy Volunteers) Interventions:   Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine;   Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine;   Biological: Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine;   Biological:  Yellow fever vaccine Sponsor:   Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Lassa fever outbreaks West Africa have caused up to 10,000 deaths annually. Primary infection occurs from contact with Lassa virus-infected rodents and exposure to their excreta, blood, or meat. Incubation takes 2 to 21  days. Symptoms are difficult to distinguish from malaria, typhoid, dengue, yellow fever, and other viral hemorrhagic fevers. Clinical manifestations range from asymptomatic, to mild, to severe fulminant disease. Ribavirin can improve outcomes. Overall mortality is between 1% and 15%. Lassa fever s hould be considered in the differential diagnosis with travel to West Africa. There is an urgent need for...
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
CONCLUSIONS This study contributed to the knowledge on the profile of confirmed cases of high severity yellow fever. The main factors associated with death were changes in renal excretion and elevated serum transaminases, especially ALT. High lethality emphasizes the need for early diagnosis and treatment, and the importance of increasing vaccination coverage.RESUMO OBJETIVO Descrever o perfil cl ínico-epidemiológico dos casos confirmados de febre amarela internados em hospital geral de referência para doenças infecciosas no estado do Rio de Janeiro, Brasil, de 11 de março de 2017 a 15 de ...
Source: Revista de Saude Publica - Category: International Medicine & Public Health Source Type: research
hard J.P. Brown Yellow fever virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by mosquito vectors to humans from primate reservoirs. Sporadic outbreaks of YFV occur in endemic tropical regions, causing a viral hemorrhagic fever (VHF) associated with high mortality rates. Despite a highly effective vaccine, no antiviral treatments currently exist. Therefore, YFV represents a neglected tropical disease and is chronically understudied, with many aspects of YFV biology incompletely defined including host range, host–virus interactions and correlates of host immunity and pathogenicity. In this a...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
More News: Allergy & Immunology | Vaccines | Yellow Fever | Yellow Fever Vaccination